Verve Therapeutics Q3 2021 Earnings Report
Key Takeaways
Verve Therapeutics reported a net loss of $22.7 million for the third quarter of 2021, with cash, cash equivalents, and marketable securities totaling $389.2 million as of September 30, 2021. The company's pipeline progress includes VERVE-101 clinical initiation on track for 2022 and preclinical data highlighting liver-targeted delivery with proprietary GalNAc-LNP Technology.
VERVE-101 clinical initiation is on track for 2022, supported by data demonstrating potent and durable lowering of PCSK9 protein and LDL-C in non-human primates.
Preclinical data highlights the development of a potent, in vivo liver-targeting lipid nanoparticle (LNP) delivery technology using a novel GalNAc-targeting ligand.
Verve ended the third quarter of 2021 with $389.2 million in cash, cash equivalents, and marketable securities.
Research and development expenses increased to $17.5 million for the third quarter of 2021, driven by additional investment in preclinical studies and manufacturing activities.